Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2006

View Archived Issues

Antitumor effects of pine bark extract in skin carcinogenesis

Sunitinib inhibits RET/PTC oncogenic kinase

Pharmacokinetic study shows feasibility of teriparatide nasal spray in the elderly

Dose proportionality seen with gabapentin GR

AS-1404 slows primary mammary tumor growth in vivo

Phase I/II study investigates Reolysin for recurrent malignant glioma

Biotest to use TAP technology in anticancer therapeutics

Inex revises plan to spin out Tekmira

Medivir offers business round-up

Wyeth affirms safety profile of Effexor XR

Myogen and Novartis extend heart muscle disease research collaboration

Medicis to focus on agreed territories for Ipsen's Reloxin

Phase I trial studies IL-21 with Rituxan in NHL

DynPort begins phase II trial for recombinant plague vaccine candidate

SNX-1012 begins phase II study for chemotherapy-induced oral mucositis

Tigris licenses molecularly targeted therapies for cancer

Anesiva plans NDA filing for 3268

Abbott reports on a new AMPK activator for type 2 diabetes and the metabolic syndrome

Kos files sNDA for new Niaspan CF range of products

Nabi-HB Intravenous recommended for approval

NDA resubmission for Pennsaid

Alzheimer's disease diagnostics described in University of Pennsylvania patent

Novel agents for neurodegenerative diseases and nausea revealed

Recent patents describe new treatment options for cardiovascular diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.